Hao YP. Evaluating the role of interleukin-2 and interleukin-12 in pediatric patients with concurrent Mycoplasma pneumoniae and Epstein-Barr virus infections. World J Clin Cases 2024; 12(23): 5346-5353 [PMID: 39156096 DOI: 10.12998/wjcc.v12.i23.5346]
Corresponding Author of This Article
Yan-Ping Hao, MBBS, Doctor, Department of Pediatrics, Maternal and Child Health Hospital, No. 261 Shanhu Road, Shengzhou, Shaoxing 312400, Zhejiang Province, China. yanpingh0021@163.com
Research Domain of This Article
Pediatrics
Article-Type of This Article
Retrospective Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Clin Cases. Aug 16, 2024; 12(23): 5346-5353 Published online Aug 16, 2024. doi: 10.12998/wjcc.v12.i23.5346
Evaluating the role of interleukin-2 and interleukin-12 in pediatric patients with concurrent Mycoplasma pneumoniae and Epstein-Barr virus infections
Yan-Ping Hao
Yan-Ping Hao, Department of Pediatrics, Maternal and Child Health Hospital, Shaoxing 312400, Zhejiang Province, China
Author contributions: Hao YP independently completed the following tasks: conceptualization, data curation, formal analysis, methodology development, resource acquisition, software implementation, and original draft writing; The final writing and editing were conducted by Hao YP.
Institutional review board statement: This study was approved by the Ethics committee of Maternal and Child Health Hospital.
Informed consent statement: Written informed consent for publication was obtained from all patients and their families included in this retrospective analysis.
Conflict-of-interest statement: The authors report no relevant conflicts of interest for this article.
Data sharing statement: The datasets used and/or analyzed during the present study are available from the corresponding author on reasonable request.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Yan-Ping Hao, MBBS, Doctor, Department of Pediatrics, Maternal and Child Health Hospital, No. 261 Shanhu Road, Shengzhou, Shaoxing 312400, Zhejiang Province, China. yanpingh0021@163.com
Received: April 29, 2024 Revised: May 24, 2024 Accepted: June 11, 2024 Published online: August 16, 2024 Processing time: 67 Days and 6.5 Hours
Core Tip
Core Tip: This study presents a novel exploration of the interaction between immune response markers and co-infection outcomes in pediatric respiratory infections, focusing on Mycoplasma pneumoniae and Epstein-Barr virus. Our research addresses a critical gap in understanding the immunological dynamics in co-infected pediatric patients, offering insights into the prognostic values of interleukins interleukin-2 and interleukin-12. Through a comprehensive analysis of clinical data and a robust methodological approach, we provide evidence that serum levels of these cytokines are significantly associated with disease prognosis in co-infected individuals. The findings suggest a nuanced role of the immune system in managing co-infections, with potential implications for therapeutic strategies.
